Another recently completed phase 3 clinical trial called REDEFINE 2 , which included 1,207 adults with type 2 diabetes and overweight or obesity, found that after 68 weeks, CagriSema led to weight loss of almost 16% experts say the highest yet in the type 2 population, compared to other weight management drugs like tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) and semaglutide
Moreover, the C-terminal serine of the peptide was replaced by cysteine via site-directed mutagenesis performed with polyethylene glycol
Most clients choose to continue beyond that initial cycle, and we monitor progress with lab work at the 6-month mark to ensure everything is tracking well
Kent Holtorf, a physician who graduated from UCLA School of Medicine
Analysis of Glutathione Research Peptide behavior in laboratory redox and antioxidant pathway studies